References
- Siegel R , NaishadhamD, JemalA . Cancer statistics, 2013 . CA Cancer J. Clin.63, 11 – 30 ( 2013 ).
- Ajani JA , WinterKA, GundersonLLet al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial . JAMA299, 1914 – 1921 ( 2008 ).
- Gunderson LL , WinterKA, AjaniJAet al. Long-term update of US GI intergroup RTOG 98–11 Phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin . J. Clin. Oncol.30, 4344 – 4351 ( 2012 ).
- Mighty KK , LaiminsLA . The role of human papillomaviruses in oncogenesis . Recent Results Cancer Res.193, 135 – 148 ( 2014 ).
- McLaughlin-Drubin ME , MüngerK . Oncogenic activities of human papillomaviruses . Virus Res.143, 195 – 208 ( 2009 ).
- Howley PM . Role of the human papillomaviruses in human cancer . Cancer Res.51, s5019 – s5022 ( 1991 ).
- DeFilippis RA , GoodwinEC, WuL, DiMaioD . Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells . J. Virol.77, 1551 – 1563 ( 2003 ).
- Goodwin EC , DiMaioD . Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways . Proc. Natl Acad. Sci. USA97, 12513 – 12518 ( 2000 ).
- Scheffner M , WernessBA, HuibregtseJM, LevineAJ, HowleyPM . The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 . Cell63, 1129 – 1136 ( 1990 ).
- Kennedy EM , KornepatiAV, GoldsteinMet al. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease . J. Virol.88, 11965 – 11972 ( 2014 ).
- Zhen S , HuaL, TakahashiY, NaritaS, LiuYH, LiY . In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9 . Biochem. Biophys. Res. Commun.450, 1422 – 1426 ( 2014 ).
- Hu Zheng , YuLan, ZhuDaet al. Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells . Biomed. Res. Int. 2014, 612823 ( 2014 ).
- Friedland AE , BaralR, SinghalPet al. Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications . Genome Biol.16, 257 ( 2015 ).
- Kim MK , OsadaT, BarryWTet al. Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer . Mol. Cancer Ther.11, 1500 – 1509 ( 2012 ).
- Uronis JM , OsadaT, McCallSet al. Histological and molecular evaluation of patient-derived colorectal cancer explants . PLoS ONE7, e38422 ( 2012 ).
- Kennedy EM , KornepatiAVR, MefferdALet al. Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic . Methods91, 82 – 86 ( 2015 ).
- Suggitt M , BibbyMC . 50 years of preclinical anticancer drug screening: empirical to target-driven approaches . Clin. Cancer Res.11, 971 – 981 ( 2005 ).
- Stelzer MK , PitotHC, LiemAet al. A mouse model for human anal cancer . Cancer Prev. Res. (Phila.)3, 1534 – 1541 ( 2010 ).
- Fichtner I , SlisowW, GillJet al. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas . Eur. J. Cancer40, 298 – 307 ( 2004 ).
- Dangles-Marie V , PocardM, RichonSet al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features . Cancer Res.67, 398 – 407 ( 2007 ).
- Guenot D , GuérinE, Aguillon-RomainSet al. Primary tumour genetic alterations and intra-tumoral heterogeneity are maintained in xenografts of human colon cancers showing chromosome instability . J. Pathol.208, 643 – 652 ( 2006 ).
- Bertotti A , MigliardiG, GalimiFet al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer . Cancer Discov.1, 508 – 523 ( 2011 ).
- Tentler JJ , NallapareddyS, TanACet al. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer . Mol. Cancer Ther.9, 3351 – 3362 ( 2010 ).